Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-Versus-Host Disease Survivorship After Hematopoietic Cell Transplantation: Part IV. Patient Important Outcomes
- PMID: 39733839
- PMCID: PMC11957933
- DOI: 10.1016/j.jtct.2024.12.019
Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-Versus-Host Disease Survivorship After Hematopoietic Cell Transplantation: Part IV. Patient Important Outcomes
Abstract
Chronic graft-versus-host disease (cGVHD) occurs in approximately 1 in 5 pediatric allogeneic HCT patients and is a leading cause of late morbidity and mortality. Late effects of hematopoietic cell transplantation (HCT) may lead to long-term chronic health conditions and shortened life expectancy. In addition to direct physiologic challenges from cGVHD and other late effects, numerous patient-important outcomes impact the quality of life (QOL) of patients and their families. The Research and Education towards Solutions for Late Effects to Innovate, Excel, and Nurture (RESILIENT) after GVHD Consensus Conference was convened to better understand the overlap of cGVHD and late effects in pediatric HCT survivors. Working Committee IV: Patient Important Outcomes identified 4 key areas for focus: (1) What are the key mental health and QOL concerns of survivors of pediatric cGVHD? (2) What is the impact of cGVHD on cognitive performance and social development? (3) What multilevel social determinants of health impact cGVHD survivors, families, and communities? (4) What is the role of racial, ethnic, and socioeconomic factors on the development of cGVHD and the risk for adverse outcomes related to survivorship? For each focus area, the Working Committee reviewed the current state of the field, developed recommendations for clinical practice, and highlighted areas to prioritize for future research. Eleven recommendations were adapted and approved. Substantial overlap exists between the role of cGVHD and late effects on the QOL and mental health of childhood HCT survivors. Recommendations based on available data and consensus opinion may be helpful to improve outcomes for these patients. However, several gaps remain that need further study.
Keywords: Allo; Late-effects; Patient-important outcomes; Patient-reported outcomes; Psychosocial; Survivorship; cGVHD.
Copyright © 2025 The American Society for Transplantation and Cellular Therapy. All rights reserved.
Conflict of interest statement
Similar articles
-
Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-Versus-Host Disease Survivorship After Hematopoietic Cell Transplantation: Part I. Phases of Chronic GVHD, Supportive Care, and Systemic Therapy Discontinuation.Transplant Cell Ther. 2025 Feb;31(2):69.e1-69.e18. doi: 10.1016/j.jtct.2024.12.011. Epub 2024 Dec 17. Transplant Cell Ther. 2025. PMID: 39701289
-
Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-versus-Host Disease Survivorship after Hematopoietic Cell Transplantation: Part III. Long-Term Impact of Chronic Graft-versus-Host Disease on Endocrinologic, Cardiovascular, and Metabolic Outcomes in Survivors of Pediatric Hematopoietic Cell Transplantation.Transplant Cell Ther. 2025 May;31(5):297.e1-297.e15. doi: 10.1016/j.jtct.2025.01.891. Epub 2025 Feb 12. Transplant Cell Ther. 2025. PMID: 39952365
-
Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-versus-Host Disease Survivorship after Hematopoietic Cell Transplantation: Part II. Organ Dysfunction and Immune Reconstitution Considerations for Children with Chronic Graft-versus-Host Disease after Hematopoietic Cell Transplantation.Transplant Cell Ther. 2025 Jun;31(6):347.e1-347.e17. doi: 10.1016/j.jtct.2025.01.885. Epub 2025 Jan 22. Transplant Cell Ther. 2025. PMID: 39855565
-
Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.Transplant Cell Ther. 2022 Jun;28(6):335.e1-335.e17. doi: 10.1016/j.jtct.2021.10.013. Epub 2021 Oct 29. Transplant Cell Ther. 2022. PMID: 34757220 Free PMC article.
-
[Recent advances in prevention and treatment of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].Rinsho Ketsueki. 2024;65(5):401-411. doi: 10.11406/rinketsu.65.401. Rinsho Ketsueki. 2024. PMID: 38825520 Review. Japanese.
References
-
- Haroun E, Agrawal K, Leibovitch J, et al. Chronic graft-versus-host disease in pediatric patients: Differences and challenges. Blood reviews. 2023;60:101054. - PubMed
-
- Nishitani M, Graham R-AT, Wang T, et al. Graft Vs Host Disease (GVHD) in Pediatric Hematopoietic Stem Cell Transplant (HCT) Recipients and Impact on Overall Survival: A CIBMTR Analysis. Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy. 2024;30:S49–S50.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources